Kornimate/medical-research-clean huggingface dataset:
photobiomodulation on muscle recovery in professional soccer players

Conditions: Muscle Development

Summary: background: photobiomodulation with low-level laser therapy (lllt) has been widely used in clinical practice for diverse purposes, such as modulation of the inflammatory process, acceleration of the tissue repair process, pain relief and the enhancement of post-exercise recovery. studies have demonstrated a beneficial interaction between photobiomodulation and the production of creatine kinase, with a reduction in the release of this marker of muscle damage when laser and/or leds is administered prior to high-intensity physical activity. the aim of the proposed study is to determine the influence of pre-exercise phototherapy on post-exercise muscle recovery. methods: a randomized, cross-over, sham-controlled, double-blind, clinical trial is proposed. the participants will be healthy professional soccer players aged 15 to 20 years from the same team with a body mass index within the ideal range (20 to 25 kg/m2) and no history of lower limb musculoskeletal injuries or surgery or back surgery in the previous six months. the athletes will be allocated to two groups based on the previously calculated sample size and will be blinded to allocation. creatine kinase will be measured and the subjective perception of fatigue will be determined for each participant. the volunteers will then be randomly allocated to group a, which will receive active phototherapy, and group b, which will receive sham phototherapy. the athletes will undergo reevaluations immediately after as well as 48 hours after a football match. the data will be submitted to statistical analysis and the level of significance will be set to 5%.


Eligibility criteria:
inclusion criteria: * healthy professional soccer players aged 15 to 20 years from the same team with a body mass index in the ideal range (20 to 25 kg/m2) will be included in the study. exclusion criteria: * a history of musculoskeletal injuries and/or surgeries in the lower limbs or back surgery in the previous six months

Keywords: photherapy photobiomodulation creatine kinase soccer muscle recovery
efficacy study of robotic surgery for rectal cancer

Conditions: Rectal Neoplasm

Summary: after introducing minimally invasive surgery, robotic surgery has been increasingly used in colorectal cancer. however, there is a few prospective study for robotic surgery. the aim of this trial is to evaluate the effectiveness and safety of robotic surgery in mid or low rectal cancer.

this study was designed as randomized phase ii trial (laparoscopic versus robotic). the primary end point is quality of mesorectal excision.

Eligibility criteria:
inclusion criteria: * mid or low rectal cancer (within 9cm from anal verge) * pathologically proven as adenocarcinoma * written informed consent * no severe functional disability in lung and heart exclusion criteria: * invading adjacent organ * distant metastasis (lung, liver, brain, bone, distant lymph nodes etc.) * lateral pelvic lymph node metastasis * have severe concomitant disease that might limit compliance or completion of the protocol. * have any other malignancy that might impact 5-year survival or might be potentially confused with rectal cancer. * if female, be pregnant or breast feeding. * hereditary colorectal cancer (hnpcc, fap etc) * emergency operation

Keywords: rectal cancer robotic surgery laparoscopic surgery
photon/proton radiation therapy for cancers of the nasal cavity and/or paranasal sinuses

Conditions: Cancers of Nasal Cavity; Cancers of Paranasal Sinuses

Summary: the purpose of this study is to collect information from a questionnaire and medical records to see what effects proton radiation has on cancer and collect and analyze morbidity outcomes: incidence of xerostomia (dry mouth) and tumor control.

the study is non interventional outcomes protocol designed to collect information from a questionnaire and medical records to see what effects proton radiation has on cancer and collect and analyze morbidity outcomes: incidence of xerostomia (dry mouth) and tumor control.

Eligibility criteria:
inclusion criteria: * cancer of nasal cavity and/or paranasal sinuses. * will receive treatment with proton radiation. exclusion criteria: * evidence of distant metastasis. * previous radiation for head and neck cancer.

Keywords: nasal cavity paranasal sinuses proton radiation outcomes
immediate effects of superficial heat associated with elongation in the posttraumatic elbow contracture

Conditions: Contracture of Elbow Joint

Summary: the elbow contracture is a secondary injury that can occur after direct trauma, causing the patient to have limitations in their range of motion. objective evaluation protocols that help in decision making for the indication of these therapeutic resources have great value in rehabilitation, as they reduce unnecessary expenses and improve the assertiveness in the indication of this resource. objective: to verify the immediate effects of superficial heat associated with sustained stretching through muscle activity and range of motion in the posttraumatic contractures of the elbow seeking the best indication of orthosis. methods: characterized as a randomized crossover type clinical trial. sample of 20 adult subjects, of both sexes, over 18 years old, with elbow stiffness due to fractures and / or dislocations with indication of orthosis use. patients will be divided into 2 randomly assigned intervention groups: the control group (cg) who will perform the 10 'sustained stretching drawn by a defined load through maximal voluntary isometric contraction (mvic) and the modified weeks group (gwm) will perform 20 'of surface heat through the swirl and soon after the stretching sustained by 10' with already defined load. all patients will undergo an initial assessment and will participate in all 2 interventions while respecting a 7 day washout period. goniometry and the visual analogue scale will be applied at the beginning and end of the interventions. the delsys® brand equipment will be used to collect the electromyographic data. placement and positioning of the electrodes will follow the determinations of the seniam protocol. the activation of the brachial, brachioradial and triceps brachii muscles during the mvic will be analyzed and also during the respective intervention protocols.


Eligibility criteria:
inclusion: * patients between the ages of 18 and 60 * of both sexes * who present elbow stiffness with flexural contractures resulting from fractures and / or dislocations, * who are in the stages of fibroblastic healing and remodeling * will be selected, with indication of use of bracing for gain of range of motion * whether or not undergoing rehabilitation either after conservative or surgical orthopedic treatment exclusion: * individuals who have clinical or surgical restrictions to perform activities of daily living * therapeutic exercises or use of orthoses * who have lesions in the central nervous system * open lesions * moderate to high intensity pain to sustained passive stretching

Keywords: elbow stretching joint amplitude electromyography surface heat orthosis posttraumatic
a study to test how a new long-acting insulin (insulin icodec) works in the body of people from china with type 2 diabetes

Conditions: Diabetes Mellitus, Type 2

Summary: this study is looking at the way insulin icodec stays and moves over time in the blood after injections in chinese people with type 2 diabetes. participants will get insulin icodec once a week for 6 weeks. the medicine will be injected under the skin of the thigh. there will also be a run-in period that will last between 1 week and 8 weeks with daily doses of insulin degludec before start on insulin icodec. the study will last for about 15 to 22 weeks. participants will have about 17 visits with the study doctor including phone contact during your run-in period. participants will have blood samples taken at the clinic visits. several samples of participants blood will be taken for up to 48 hours after getting the first and the last dose of insulin icodec. participants must be a chinese person diagnosed with type 2 diabetes for at least 6 months and be on basal insulin treatment for at least 2 months before participating in the study. women: women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period


Eligibility criteria:
inclusion criteria: * chinese male or female * aged 18-64 years (both inclusive) at the time of signing informed consent * body mass index between 18 and 38 kg/m\^2 (both inclusive) * hba1c (glycated haemoglobin) below or equal to 9% at screening * current daily basal insulin treatment greater than or equal to 0.2 (i)u/kg/day greater than or equal to 60 days prior to the day of screening with or without any of the following anti-diabetic drugs/regimens with stable doses greater than or equal to 60 days prior to the day of screening: * any metformin formulation * other oral antidiabetic drugs: dpp-4 (dipeptidyl-peptidase-4) inhibitors , sglt2 (sodium-glucose co-transporter-2) inhibitors, oral combination products (for the allowed individual oral antidiabetic drugs) * oral or injectable glp-1 (glucagon like peptide 1) receptor agonists exclusion criteria: * known or suspected hypersensitivity to trial product(s) or related products. * female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate contraceptive method (adequate contraceptive measures as required by local regulation or practice). * uncontrolled and potentially unstable diabetic retinopathy or maculopathy. verified by a fundus examination performed within 90 days prior to screening or in the period between screening and run-in. pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination. * recurrent severe hypoglycaemia (more than 1 severe hypoglycaemic event within the past 180 days) or hypoglycaemic unawareness as judged by the investigator or hospitalisation for diabetic ketoacidosis within the past 180 days prior to the day of screening
isolated during covid-19: effects of covid-19's social restrictions on loneliness and psychosocial symptomatology

Conditions: Loneliness; Depression; Anxiety; Alcohol Abuse; Drug Abuse

Summary: this study seeks to gather data and insight on epidemiologic trends of loneliness and other behaviors in the wake of the cdc recommended "social distancing" during the covid-19 pandemic. the objective of this study is to use a cross-sectional survey to assess the impact of covid-19's associated recommendations (social distancing, self-isolation, and self-quarantine) on loneliness and psychosocial symptomatology (depression, anxiety, substance abuse) on young adults (18-35 years old).


Eligibility criteria:
inclusion criteria * 18-35 years old * currently living in the united states exclusion criteria * those under 18 years, or older than 35 years * adults unable to consent * non-english-speaking adults
goals for epilepsy clinic visits trial

Conditions: Drug Resistant Epilepsy

Summary: the purpose of this project is to conduct a trial to assess whether patients that receive a tablet-based waiting room priority communication tool (the "epilepsy visit planner") have improved outcomes compared to patients that do not receive the tool. the project's hypotheses are: * patients that receive the epilepsy visit planner will have improved patient-provider communication compared to the non-planner group. * patients that receive the epilepsy visit planner will have improved quality of life scores. * the epilepsy visit planner will score highly on process measures of feasibility and acceptability, demonstrating suitability for future larger scale study. additionally, there is a related survey project that is not part of the clinical trial and will not be included in this registration information.


Eligibility criteria:
inclusion criteria - patient participants: * adults with drug-resistant epilepsy * participants receiving care through the epilepsy clinics at the university of michigan exclusion criteria - patient participants: * \<18 years old * non-english speaking * do not clearly have drug-resistant epilepsy * moderate-to-severe cognitive impairment that precludes study questionnaire completion inclusion criteria - provider participants: -university of michigan epilepsy providers exclusion criteria - provider participants: -not university of michigan epilepsy providers

Keywords: survey quality of life communication tool patient-provider communication
prediction of preeclampsia and other pregnancy complications following combined iterative screening

Conditions: Preeclampsia; Preterm Birth; Fetal Growth Restriction; Intra Uterine Fetal Death

Summary: preterm birth (ptb), preeclampsia (pe), fetal growth restriction (fgr) and intra-uterine fetal death (iufd) constitutes the main causes of perinatal morbidity and mortality and are called "great obstetrical syndromes". algorithms to predict those outcomes have been developed by combining maternal characteristics (history, age, bmi, blood pressure), biochemical (sflt-1, β-hcg, plgf, afp) and sonographic (uterine artery doppler, 3d of placenta, cervical length, nasal bone measurement, nuchal translucency) markers. another prospective observational study ("prediction study" nct 02189148) is also ongoing, which aims to validate those algorithms at the first trimester of pregnancy. recent data suggest that repeating the same measurements later in pregnancy could improve the detection rates, allowing closer monitoring of high-risk patients and potential therapeutics under investigation. the current study (prediction2) is an ancillary study of prediction and aims at validating the use of these markers in a combined iterative manner in the prediction of preeclampsia and other obstetrical outcomes.

the objective of this study is to validate the predictive values of biophysical (maternal blood pressure); biochemical (sflt-1, β-hcg, plgf, and afp) and ultrasonographic (cervical length, doppler, 3d evaluation of the placenta, 3d nasal bone) biomarkers at several timepoints for the prediction of adverse pregnancy outcomes including preterm birth, preeclampsia, fetal growth restriction and intra-uterine fetal death. these biomarkers will be evaluated at 14-16 weeks, 20-24 weeks and 30-34 weeks. those specific gestational ages have been selected because they correspond to the typical clinical/hospital visits for prenatal blood and/or ultrasound screening.

Eligibility criteria:
inclusion criteria: * nulliparous pregnant women participating in prediction study (nct02189148) exclusion criteria: * \<18 years old at recruitment; * multiple pregnancies; * fetal congenital malformation; * positive for hiv or hepatitis c; * fetal demise at recruitment; * women planning a delivery outside the participating hospitals; * women not able to provide an informed consent to the study.

Keywords: pregnancy screening doppler markers plgf sflt-1 placenta
increasing treatment efficacy using smart methods for personalizing care

Conditions: Anxiety Disorders; Post Traumatic Stress Disorder; Obsessive-Compulsive Disorder

Summary: the proposed study will determine the feasibility, tolerability, and acceptability of a study that tests: 1) personalized treatment delivery (i.e., module sequencing and treatment discontinuation timing) aimed at increasing the efficiency of care, and 2) the research protocol designed to evaluate the effects of this personalized care. a sample of 60 participants with heterogeneous anxiety disorders (and comorbid conditions, including depression) will be enrolled in a pilot sequential multiple assignment randomized trial (smart). patients will be randomly assigned to one of three sequencing conditions: transdiagnostic treatment administered in its standard module order, module sequences that prioritize capitalizing on relative strengths, and module sequences that prioritize compensating for relative weaknesses. next, after 6 sessions, participants will be randomly assigned to either continue or discontinue treatment to evaluate post-treatment change at varying levels of target engagement. this proposal will enable us to 1) test the feasibility, acceptability, and tolerability of the research protocol, treatment sequencing conditions, and early treatment discontinuation, 2) determine whether a preliminary signal that capitalization or compensation module sequencing improves treatment efficiency exists, and 3) explore preliminary associations between core process engagement at treatment discontinuation and later symptom improvement. the proposed study, and the subsequent research it will support, will inform evidence-based decision rules to make existing treatments more efficient, ultimately reducing patient costs and increasing the mental health service system's capacity to address the needs of more individuals.


Eligibility criteria:
inclusion criteria: * diagnosis of at least one anxiety disorder, trauma- or stressor-related disorder, or obsessive-compulsive disorder * fluent in english * medication stability exclusion criteria: * concurrent therapy * psychological condition that would be better addressed by alternative treatments * have received more than 5 sessions of cognitive behavioral therapy in the past 5 years

Keywords: unified protocol cognitive behavioral therapy personalization
meal glycaemic index and exercise after gastric bypass

Conditions: Roux-en-Y Gastric Bypass; Obesity

Summary: the study will evaluate postprandial glucose excursions and gut hormone secretion after ingestion of meals with different glycaemic index (gi) values (high vs low) followed by an acute bout of exercise or rest in gastric bypass operated subjects and matched control subjects.


Eligibility criteria:
rygb patients: inclusion criteria: * undergone roux-en-y gastric bypass (rygb) without complications at least 12 months prior to inclusion. * achieved \> 50% excess bmi loss * weight stability (no fluctuations over ± 5 kg the last 3 months) * hba1c \< 48 mmol/mol before and after surgery without the use of anti-diabetic medication * the participant must be able to ingest the meals exclusion criteria: * low hemoglobin levels (\< 6.5 mm) * pregnancy (determined by human chorionic gonadotropin (hcg) test) or breastfeeding * dysregulated thyroid gland affection * the use of medication which affects heart frequency (i.e. beta-blockers) * complications following rygb consisting of dysphagia or other problems associated with ingestion of normal foods (i.e. vomit, diarrhea or strong abdominal pain). control group: inclusion criteria: * matched with the rygb patients on gender, age (± 5 years), menopausal state (pre- versus post-menopausal) and bmi (± 3 points). * weight stable ( ± 5 kg during 3 months) * hba1c \< 48 mmol/mol exclusion criteria: * prior bariatric surgery or prior surgery in the upper gastrointestinal tract.

Keywords: gut hormones glucose excursions
explore the effect of gynostemma pentaphyllum on patients with metabolic syndrome

Conditions: Metabolic Syndrome

Summary: previous research shows that gypenoside could keep blood lipid and blood sugar under control in an effective way. in this study, we intend to explore whether gypenosides have clinical improvement effects on metabolic diseases such as diabetes, hyperlipidemia, and non-alcoholic fatty liver and their cardiovascular protective potential. it is designed to recruit 150 patients with metabolic syndrome diagnosed who meet the criteria for enrollment, and randomly divide them into three groups. gynostemma powder, with two different saponins content (12% and 8%) from pingli county, shaanxi province, and spinach powder with almost no saponins were used to conduct the intervention on patients. patients will be followed up regularly at the beginning of each month from the first enrollment until the third month. at each follow-up, data of patient's anthropometric indicators as well as clinical inspection indicators related to metabolism (blood routine, liver function, etc.) will be recorded. in addition, patient's blood, hair, urine, and stool samples will be collected to further explore the mechanism of diseases.


Eligibility criteria:
inclusion criteria: * low-density lipoprotein (ldl) cholesterol ≥130 mg/dl (3.4 mmol/l ), or conforms to the diagnosis criteria for metabolic syndrome (based on the mets diagnostic criteria developed by idf and aha in 2009), that is, having three or more of the following traits: 1. waist circumference ≥90 cm in men or ≥80 cm in women; 2. elevated tg (drug treatment for elevated tg is an alternate indicator) ≥150 mg/dl (1.7 mmol/l); 3. reduced hdl-c (drug treatment for reduced hdl-c is an alternate indicator) \< 40 mg/dl (1.03 mmol/l) in males \< 50 mg/dl (1.29 mmol/l) in females; 4. elevated blood pressure (anti-hypertensive drug treatment in a patient with a history of hypertension is an alternate indicator). systolic ≥ 130 and/or diastolic ≥ 85 mmhg; 5. elevated fasting glucose (drug treatment for elevated glucose is an alternate indicator) ≥ 100 mg/dl (5.6 mmol/l). * be over 18 years old or younger than 80 years old, no gender limit. * have a good follow-up compliance and can be followed up for more than 3 months; * from 2 weeks before enrollment to the end of the entire trial, the treatment regimen will not change. exclusion criteria: * pregnant and lactating women; * allergic or toxic reactions to gynostemma and other drugs; * infectious diseases such as viral hepatitis, aids, syphilis, tuberculosis are active; * after drug treatment, still showing high blood sugar (fasting blood glucose higher than 200mg/dl, 11.1mmol/l) or hyperlipidemia, or hypertension (higher than 180/110 mmhg); * any conditions judged by the investigator that affect enrollment.